To ensure their future, Big Pharma is multiplying biotech acquisitions
Faced with the expiry of patents for some of their most lucrative drugs, major pharmaceutical groups are on the lookout for the next blockbuster treatments on the market.
We haven't written up this one. Le Monde Economie has the full story — the link below goes straight to it.